AU2020397933A1 - Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease - Google Patents

Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease Download PDF

Info

Publication number
AU2020397933A1
AU2020397933A1 AU2020397933A AU2020397933A AU2020397933A1 AU 2020397933 A1 AU2020397933 A1 AU 2020397933A1 AU 2020397933 A AU2020397933 A AU 2020397933A AU 2020397933 A AU2020397933 A AU 2020397933A AU 2020397933 A1 AU2020397933 A1 AU 2020397933A1
Authority
AU
Australia
Prior art keywords
subject
unit dosage
dosage form
active agent
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020397933A
Other languages
English (en)
Inventor
David Arthur Berry
Timothy F. Briggs
Leonard Buckbinder
John Patrick Casey Jr.
Mi-Jeong Kim
Anna LIANG
Anushya PANDIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flagship Pioneering Innovations V Inc
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of AU2020397933A1 publication Critical patent/AU2020397933A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020397933A 2019-12-05 2020-12-04 Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease Abandoned AU2020397933A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962944258P 2019-12-05 2019-12-05
US62/944,258 2019-12-05
US202063074770P 2020-09-04 2020-09-04
US63/074,770 2020-09-04
PCT/US2020/063307 WO2021113635A1 (en) 2019-12-05 2020-12-04 Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
AU2020397933A1 true AU2020397933A1 (en) 2022-06-30

Family

ID=76221221

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020397933A Abandoned AU2020397933A1 (en) 2019-12-05 2020-12-04 Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease

Country Status (6)

Country Link
US (1) US20220296555A1 (https=)
EP (1) EP4069208A4 (https=)
JP (1) JP2023505233A (https=)
AU (1) AU2020397933A1 (https=)
CA (1) CA3163526A1 (https=)
WO (1) WO2021113635A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3205899B2 (ja) * 1997-07-18 2001-09-04 株式会社浅井ゲルマニウム研究所 糖尿病又は腎不全に伴う合併症の診断試薬
WO2000015215A1 (en) * 1998-09-15 2000-03-23 Korea Research Institute Of Bioscience And Biotechnology Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases
JP2000256259A (ja) * 1999-03-11 2000-09-19 Nippon Zoki Pharmaceut Co Ltd メイラード反応阻害剤
US8501676B2 (en) * 2004-07-19 2013-08-06 N.V. Nutricia Preparation for use of aspartate for regulating glucose levels in blood
CN101167802B (zh) * 2006-10-25 2011-04-20 中国科学院上海生命科学研究院 肉桂提取物的制备方法、肉桂提取物、其组合物以及用途
CA2737431C (en) * 2008-09-18 2016-03-29 Nippon Zoki Pharmaceutical Co., Ltd. Amino acid derivative
JP2016216378A (ja) * 2015-05-15 2016-12-22 公立大学法人岡山県立大学 ウロリチン類を含有する抗糖化剤
JP2017171638A (ja) * 2016-03-25 2017-09-28 花王株式会社 骨強度改善剤

Also Published As

Publication number Publication date
EP4069208A4 (en) 2024-01-10
CA3163526A1 (en) 2021-06-10
US20220296555A1 (en) 2022-09-22
JP2023505233A (ja) 2023-02-08
WO2021113635A1 (en) 2021-06-10
EP4069208A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
US20240180941A1 (en) Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
AU2014236719B2 (en) Compounds and methods for inducing chondrogenesis
JP2009527551A (ja) ２型糖尿病の治療用および避妊薬としてのシクロリグナンの使用
IL229246A (en) Partially saturated tricyclic compounds and preparation and use methods
WO2010040286A1 (zh) 三乙酰基-3-羟基苯基腺苷及其调血脂的用途
JP2018509474A (ja) インダン酢酸誘導体を用いる肝疾患の治療方法
CN111662294A (zh) 一类具有降解Btk活性的化合物
WO2020077361A1 (en) Compounds and methods of their use
RU2549441C2 (ru) Способы и фармацевтические композиции для лечения синдрома дауна
EP1744740A1 (en) Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases
US20220296555A1 (en) Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
US20220296563A1 (en) Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
CN119350175B (zh) 一类新型酰基苯丙氨酸衍生物、其制备方法及其作为药物的用途
MXPA04004572A (es) Metodo para el tratamiento de enfermedades autoinmunes.
RU2349587C2 (ru) Производное фенилуксусной кислоты и его применение
CA2532805A1 (en) Pharmaceutical composition
CN106432026A (zh) 一类对糖尿病具有潜在治疗活性的化合物
WO2021247963A1 (en) (s)-alpha-fluoromethyltyrosine as decarboxylase inhibitors for use in the treatment of hypotension
CN1498109A (zh) 膀胱感觉过敏治疗剂
EA015503B1 (ru) Применение 4-циклопропилметокси-n-(3,5-дихлор-1-оксидопиридин-4-ил)-5-(метокси)пиридин-2-карбоксамида для лечения черепно-мозговых травм
JP2008285452A (ja) ＰＰＡＲα／γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬
CZ368099A3 (cs) Sloučenina obecného vzorce 5-(2- imidazolinylamino)benzimidazol, která je synergista alfa-2 adrenoceptoru a je použitelná pro léčení poruch modulovaných alfa-2 adrenoceptory

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application